Literature DB >> 31056398

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.

Jo Ishizawa1, Sarah F Zarabi2, R Eric Davis3, Ondrej Halgas4, Takenobu Nii1, Yulia Jitkova5, Ran Zhao1, Jonathan St-Germain5, Lauren E Heese1, Grace Egan5, Vivian R Ruvolo1, Samir H Barghout2, Yuki Nishida1, Rose Hurren5, Wencai Ma6, Marcela Gronda5, Todd Link7, Keith Wong4, Mark Mabanglo8, Kensuke Kojima9, Gautam Borthakur1, Neil MacLean5, Man Chun John Ma3, Andrew B Leber5, Mark D Minden2, Walid Houry10, Hagop Kantarjian11, Martin Stogniew12, Brian Raught2, Emil F Pai13, Aaron D Schimmer14, Michael Andreeff15.   

Abstract

The mitochondrial caseinolytic protease P (ClpP) plays a central role in mitochondrial protein quality control by degrading misfolded proteins. Using genetic and chemical approaches, we showed that hyperactivation of the protease selectively kills cancer cells, independently of p53 status, by selective degradation of its respiratory chain protein substrates and disrupts mitochondrial structure and function, while it does not affect non-malignant cells. We identified imipridones as potent activators of ClpP. Through biochemical studies and crystallography, we show that imipridones bind ClpP non-covalently and induce proteolysis by diverse structural changes. Imipridones are presently in clinical trials. Our findings suggest a general concept of inducing cancer cell lethality through activation of mitochondrial proteolysis.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute myeloid leukemia; cancer; imipridone; lymphoma; mitochondrial ClpP; mitochondrial proteolysis; oxidative phosphorylation; respiratory chain complex

Mesh:

Substances:

Year:  2019        PMID: 31056398      PMCID: PMC6620028          DOI: 10.1016/j.ccell.2019.03.014

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  66 in total

1.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

2.  Dysregulation of bacterial proteolytic machinery by a new class of antibiotics.

Authors:  Heike Brötz-Oesterhelt; Dieter Beyer; Hein-Peter Kroll; Rainer Endermann; Christoph Ladel; Werner Schroeder; Berthold Hinzen; Siegfried Raddatz; Holger Paulsen; Kerstin Henninger; Julia E Bandow; Hans-Georg Sahl; Harald Labischinski
Journal:  Nat Med       Date:  2005-10-02       Impact factor: 53.440

3.  Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia.

Authors:  Alicia Cole; Zezhou Wang; Etienne Coyaud; Veronique Voisin; Marcela Gronda; Yulia Jitkova; Rachel Mattson; Rose Hurren; Sonja Babovic; Neil Maclean; Ian Restall; Xiaoming Wang; Danny V Jeyaraju; Mahadeo A Sukhai; Swayam Prabha; Shaheena Bashir; Ashwin Ramakrishnan; Elisa Leung; Yi Hua Qia; Nianxian Zhang; Kevin R Combes; Troy Ketela; Fengshu Lin; Walid A Houry; Ahmed Aman; Rima Al-Awar; Wei Zheng; Erno Wienholds; Chang Jiang Xu; John Dick; Jean C Y Wang; Jason Moffat; Mark D Minden; Connie J Eaves; Gary D Bader; Zhenyue Hao; Steven M Kornblau; Brian Raught; Aaron D Schimmer
Journal:  Cancer Cell       Date:  2015-06-08       Impact factor: 31.743

4.  A human homologue of Escherichia coli ClpP caseinolytic protease: recombinant expression, intracellular processing and subcellular localization.

Authors:  T J Corydon; P Bross; H U Holst; S Neve; K Kristiansen; N Gregersen; L Bolund
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

5.  Crystallography and mutagenesis point to an essential role for the N-terminus of human mitochondrial ClpP.

Authors:  Sung Gyun Kang; Michael R Maurizi; Mark Thompson; Timothy Mueser; Bijan Ahvazi
Journal:  J Struct Biol       Date:  2004-12       Impact factor: 2.867

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

Authors:  Eleni D Lagadinou; Alexander Sach; Kevin Callahan; Randall M Rossi; Sarah J Neering; Mohammad Minhajuddin; John M Ashton; Shanshan Pei; Valerie Grose; Kristen M O'Dwyer; Jane L Liesveld; Paul S Brookes; Michael W Becker; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2013-01-17       Impact factor: 24.633

8.  Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides.

Authors:  Kıvanç Birsoy; Richard Possemato; Franziska K Lorbeer; Erol C Bayraktar; Prathapan Thiru; Burcu Yucel; Tim Wang; Walter W Chen; Clary B Clish; David M Sabatini
Journal:  Nature       Date:  2014-03-16       Impact factor: 49.962

9.  Mitochondrial unfolded protein response controls matrix pre-RNA processing and translation.

Authors:  Christian Münch; J Wade Harper
Journal:  Nature       Date:  2016-06-22       Impact factor: 49.962

10.  Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells.

Authors:  Elodie M Kuntz; Pablo Baquero; Alison M Michie; Karen Dunn; Saverio Tardito; Tessa L Holyoake; G Vignir Helgason; Eyal Gottlieb
Journal:  Nat Med       Date:  2017-09-18       Impact factor: 53.440

View more
  73 in total

1.  Mitochondria regulate AML differentiation independent of oxidative phosphorylation and metabolism.

Authors:  Rashim Pal Singh; Aaron D Schimmer
Journal:  Mol Cell Oncol       Date:  2020-09-28

Review 2.  Mitochondrial Stress Response and Cancer.

Authors:  Jordan O'Malley; Rahul Kumar; Joseph Inigo; Nagendra Yadava; Dhyan Chandra
Journal:  Trends Cancer       Date:  2020-05-22

Review 3.  Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy.

Authors:  Jenna L Carter; Katie Hege; Jay Yang; Hasini A Kalpage; Yongwei Su; Holly Edwards; Maik Hüttemann; Jeffrey W Taub; Yubin Ge
Journal:  Signal Transduct Target Ther       Date:  2020-12-18

4.  An allosteric switch regulates Mycobacterium tuberculosis ClpP1P2 protease function as established by cryo-EM and methyl-TROSY NMR.

Authors:  Siavash Vahidi; Zev A Ripstein; Jordan B Juravsky; Enrico Rennella; Alfred L Goldberg; Anthony K Mittermaier; John L Rubinstein; Lewis E Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-02       Impact factor: 11.205

Review 5.  Targeting apoptosis in cancer therapy.

Authors:  Benedito A Carneiro; Wafik S El-Deiry
Journal:  Nat Rev Clin Oncol       Date:  2020-03-23       Impact factor: 66.675

6.  Mitochondrial dynamics and quality control are altered in a hepatic cell culture model of cancer cachexia.

Authors:  Nishant P Visavadiya; Gabriel S Pena; Andy V Khamoui
Journal:  Mol Cell Biochem       Date:  2020-08-14       Impact factor: 3.396

Review 7.  Targeting mitochondrial respiration for the treatment of acute myeloid leukemia.

Authors:  Jenna L Carter; Katie Hege; Hasini A Kalpage; Holly Edwards; Maik Hüttemann; Jeffrey W Taub; Yubin Ge
Journal:  Biochem Pharmacol       Date:  2020-10-02       Impact factor: 5.858

8.  Loss of Mitochondrial Protease CLPP Activates Type I IFN Responses through the Mitochondrial DNA-cGAS-STING Signaling Axis.

Authors:  Sylvia Torres-Odio; Yuanjiu Lei; Suzana Gispert; Antonia Maletzko; Jana Key; Saeed S Menissy; Ilka Wittig; Georg Auburger; A Phillip West
Journal:  J Immunol       Date:  2021-03-17       Impact factor: 5.422

Review 9.  Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors.

Authors:  Courtney L Jones; Anagha Inguva; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2021-03-04       Impact factor: 24.633

10.  ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer.

Authors:  Isacco Ferrarini; Anna Louie; Lanlan Zhou; Wafik S El-Deiry
Journal:  Mol Cancer Ther       Date:  2021-06-17       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.